ImmunAbs
Korea - SeoulBiotechnology
Focus: ImmunAbs is a Korea-based biotechnology company specializing in antibody discovery, positioned in the early-stage biotech segment. Limited public data restricts clear assessment of scale and market position.
Profile data last refreshed 22h ago · AI intelligence enriched 2w ago
Open Jobs
0
About ImmunAbs
AI assessmentNot HiringNo open roles listed right now. Follow ImmunAbs to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
IM-101 Part A
Myasthenia GravisClinical Trials (1)
NCT07250750A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
Phase 1/2Help build intelligence for ImmunAbs
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.